Effect of the neoadjuvant chemotherapy on surgical treatment muscle-invasive bladder cancer.

Summary. The aim of the work was to study the influence of neoadjuvant chemotherapy of the tumor process and surgical treatment of muscle-invasive bladder cancer. Prospectively evaluated the effectiveness of neoadjuvant chemotherapy and quality of life in 41 patients with muscle-invasive bladder cancer. Complete response of tumors diagnosed in 4 (9.8%), partial response — in 24 (58.5%), stable disease — in 11 (26.8%) and progressive disease — in 2 (4.9%) patients. In 4 (9.8%) cases the control cystoscopy with transurethral biopsy of the bladder wall, in 6 (14.6%) — open, in 18 (43.9%) — transurethral resection bladder wall of the tumor and 11 (26.8%) —a radical cystectomy was done. In 2 (4,9%) patient with absolute contraindications to cystectomy, performed palliative transurethral resection  of the bladder wall of the tumor. The neoadjuvant chemotherapy reliably cause regression of muscle-invasive bladder cancer in 68.3%, reducing the depth of invasion in 26.8% cases, that allows you to perform organ-sparing surgery and thus increases your overall 2-year survival rate to 85,4% and improves quality of life by 25%.